ロシア政府が第二の国産ワクチンを承認 ファイザーが日本で試験開始: ずくなしの冷や水

2020年10月20日

ロシア政府が第二の国産ワクチンを承認 ファイザーが日本で試験開始





TASS2020/10/23
Austria expresses interest in Russian coronavirus vaccine
The new director general of the Austrian-Russian Friendship Society revealed that a proposal was voiced that either the organization's members travel to Russia to get vaccinated or the vaccine is shipped to Austria

ロイター2020年10月20日
米ファイザー、新型コロナワクチンの臨床試験を日本で開始
[東京 20日 ロイター] - 米製薬大手ファイザーPFE.Nは20日、ドイツのバイオ医薬品ビオンテック22UAy.Fと共同で開発している新型コロナウイルス感染症ワクチンについて、日本での第1/2相臨床試験を開始したと発表した。
現在、米国、ドイツ、ブラジルなどの治験施設で4万4000人が第2/3相試験に参加しており、これらと日本の試験データを使って日本での製造販売承認を申請する予定だという。
ファイザーとビオンテックは7月末、臨床開発が成功し、規制当局の承認が得られた場合、1億2000万回分のワクチンを来年上半期に日本で供給することについて日本政府と合意したと発表している。

RT2020/10/14
Two months after pioneering ‘Sputnik V’ launched, Putin announces registration of 2nd Russian Covid-19 vaccine, says 3rd on way
By Jonny Tickle
President Vladimir Putin announced on Wednesday that Russia has registered its second domestic Covid-19 vaccine, with a third already on the way. A phase-three trial, with 40,000 volunteers, is due to begin in the near future.

In August, Russia was the first country to announce the registration of a Covid-19 vaccine, which has since been taken by thousands of Muscovites, as part of its final trial phase. With a second formula registered and another around the corner, Russia will soon have a wide range of options.

The name of the new vaccine is EpiVacCorona and it is being produced in Siberia by Vector, a biological research center. Located near the city of Novosibirsk, Vector is a world-class virology and biotechnology facility, and has one of the world’s most comprehensive collections of viruses, including Ebola, SARS, and smallpox.

According to Deputy Prime Minister Tatyana Golikova, 60,000 doses of the vaccine are due to be released soon. She also said that 40,000 volunteers will participate in a third-phase clinical trial, including people over 65 years-old. Thus far, just 100 volunteers have taken the vaccine.

Speaking to Golikova, the president expressed his will for all doses produced in Russia to remain within the country, explaining that formulas for the use of foreign nations should be made abroad.

The third vaccine is being produced by the Chumakov Federal Scientific Center, in Moscow.

According to Alexander Ryzhikov, the head of Vector’s zoonotic infections and influenza department, the second Russian vaccine should create immunity for at least six months, and is made in a way that people can be vaccinated multiple times.

“It forms a targeted immune response, and there is no need to worry about (the) long-term effects of revaccination,” he said. The vaccine is also completely safe, with the only side-effect being a mild pain at the site of injection, Ryzhikov added.


posted by ZUKUNASHI at 22:24| Comment(0) | Covid19
この記事へのコメント
コメントを書く
お名前: [必須入力]

メールアドレス: [必須入力]

ホームページアドレス:

コメント: [必須入力]

※ブログオーナーが承認したコメントのみ表示されます。